This phase 1 clinical trial examines the escalation and safety of humanized anti-GD2 antibody doses in combination with granulocyte-macrophage colony-stimulating factor for treating patients with high-risk neuroblastoma.
https://ift.tt/2QKqO6S
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου